HDAC9 and primary cutaneous T-cell non-Hodgkin lymphoma: Vorinostat (SAHA, Zolinza) was the first HDAC inhibitor approved by the FDA in 2006, achieving a total remission rate of 30% in patients with recurrent or refractory cutaneous T-cell lymphoma (CTCL) [56].